MedTrace Logo

Alzheimer's Disease Acitretin Medication

NCT01078168 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2018-02-05

Study results available
· View outcomes & findings →

Summary

The trials investigates the changes of cerebral spinal fluid (CSF) soluble alpha-secretase cleaved APP (APPsα) levels under oral therapy with acitretin 30mg daily in patients with mild to moderate Alzheimer's disease (AD).The present study aims to demonstrate an enhancement of the α-secretase activity by acitretin as measured by increased CSF APPSα levels in human AD. Second, the safety and tolerability of acitretin in AD patients should be proven.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Acitretin

30mg per day from Day 1 to Day 28

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Alzheimer Forschungsinitiative e.V. (AFI)

    collaborator UNKNOWN

  • K. Lieb

    lead OTHER

Principal Investigators

  • Andreas Fellgiebel, PD Dr. · Department of psychiatry and psychotherapy, University medical center of the Johannes Gutenberg-University Mainz, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2013-01-31
Completion
2013-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01078168 on ClinicalTrials.gov